Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

European stocks close higher on UK inflation cheer, Argenx sinks on failed drug study

Published 20/12/2023, 08:34
© Reuters. The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, November 18, 2023.    REUTERS/Staff/file photo

By Ankika Biswas, Khushi Singh and Sruthi Shankar

(Reuters) - European stocks closed higher on Wednesday after signs of fast-cooling inflation in Britain boosted UK equities, while shares of Belgian pharmaceutical company Argenx sank after a failed drug study.

The pan-European STOXX 600 edged up 0.3%, with UK's blue-chip FTSE 100 index jumping 1.0% after data showed British inflation plunged in November to its lowest rate in over two years, driving up bets that the Bank of England will cut interest rates in the first half of next year.

Other main regional markets, however, paused after a recent run of gains as investors weighed comments from European Central Bank (ECB) policymakers.

Two of the ECB's most prominent hawks including Bundesbank President Joachim Nagel and his Dutch colleague Klaas Knot joined the chorus of policymakers trying to talk traders out of betting on upcoming interest rate cuts.

Equity markets in the U.S. and Europe have rallied in recent weeks on expectations of a dovish policy pivot by the Federal Reserve and the ECB following evidence of falling inflation and slowing economic growth.

"The ghost of inflation has been transformed into Father Christmas for UK investors today," noted Chris Beauchamp, chief market analyst at online trading platform IG.

"Stocks do seem fair set to rally into Christmas and given the still underweight allocations among fund managers, there may be enough fuel in the tank to keep the rally going well into January and beyond."

Data showed German producer prices fell more than expected in November, a day after another set confirmed that euro zone inflation slowed sharply to 2.4% last month on a year-on-year basis.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Overall, hopes of monetary policy easing next year have pushed the STOXX 600 up almost 13% year-to-date, with the German DAX and France's CAC 40 trading near record highs.

Among single stock movers on Wednesday, Argenx slumped 25.6% to post its biggest percentage loss on record after its autoimmune drug failed a study testing it in patients with two skin conditions.

The slump dragged Belgium's blue-chip BEL20 index down 2.4%.

Telefonica (BME:TEF) climbed 3.2% to top the STOXX 600 after the Spanish government said it would buy a stake of up to 10% in the company in a counterbalance to a similar acquisition by Saudi Arabia's STC.

The broader telecommunications index advanced 1.2%.

Deutsche Post (ETR:DHLn) lost 1.9% after U.S. peer FedEx (NYSE:FDX) cut its full-year revenue forecast and reported lower-than-expected quarterly profit.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.